In the animal model of ovarian cancer, the addition of the demethylating drug azacitidine to anti-CTLA-4 antibody therapy significantly elevated the expression of chemokines by NK cells and CD8+ T cells, inhibited tumor growth and prolonged survival in ovarian cancer models compared with immune checkpoint inhibition alone (126). Here, CTLA4 is linked to ovarian carcinoma.